Menu
Search
|

Menu

Close
X

AbbVie Inc ABBV.N (New York Stock Exchange)

95.41 USD
-0.84 (-0.87%)
As of 1:32 AM IST
chart
Previous Close 96.25
Open 96.27
Volume 1,205,252
3m Avg Volume 1,959,918
Today’s High 97.17
Today’s Low 95.33
52 Week High 125.84
52 Week Low 69.40
Shares Outstanding (mil) 1,586.88
Market Capitalization (mil) 153,340.20
Forward P/E 15.47
Dividend (Yield %) 0.96 ( 3.99 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.41 Mean rating from 22 analysts

KEY STATS

Revenue (mm, USD)
FY18
7,934
FY17
28,216
FY16
25,638
FY15
22,859
EPS (USD)
FY18
1.744
FY17
5.539
FY16
3.641
FY15
3.133
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
15.47
33.15
Price to Sales (TTM)
vs sector
5.18
8.04
Price to Book (MRQ)
vs sector
42.99
4.28
Price to Cash Flow (TTM)
vs sector
13.25
22.37
Total Debt to Equity (MRQ)
vs sector
1,049.45
17.43
LT Debt to Equity (MRQ)
vs sector
869.86
13.25
Return on Investment (TTM)
vs sector
18.30
13.23
Return on Equity (TTM)
vs sector
233.05
15.27

EXECUTIVE LEADERSHIP

Richard Gonzalez
Chairman of the Board, Chief Executive Officer, Since 2013
Salary: $1,638,460.00
Bonus: $4,331,250.00
William Chase
Executive Vice President, Chief Financial Officer, Since 2013
Salary: $1,008,530.00
Bonus: $1,954,550.00
Michael Severino
Executive Vice President - Research & Development, Chief Scientific Officer, Since 2014
Salary: $1,004,460.00
Bonus: $1,955,070.00
Laura Schumacher
Executive Vice President, External Affairs, General Counsel and Corporate Secretary, Since 2013
Salary: $1,008,530.00
Bonus: $1,954,550.00
Carlos Alban
Executive Vice President - Commercial Operations, Since 2013
Salary: $947,469.00
Bonus: $1,836,220.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1 N Waukegan Rd
NORTH CHICAGO   IL   60064-1802

Phone: +1847.9327900

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

SPONSORED STORIES